CD70 Recombinant Antibody: Quality Research Tool for Your Experiments

CD70 recombinant antibody is a cutting-edge research tool provided by Alpha Lifetech Incorporation, designed for researchers exploring immune responses and lymphocyte activation. CD70, a critical ligand in the cd27-CD70 pathway, plays a pivotal role in modulating T-cell responses and is integral to understanding various immunological processes, including autoimmune diseases and cancer, This high-quality recombinant antibody is engineered for exceptional specificity and affinity, ensuring reliable performance in various applications, including flow cytometry, ELISA, and immunohistochemistry. With extensive validation and consistency in results, scientists can trust this antibody to enhance their research outcomes, Alpha Lifetech is dedicated to supporting the scientific community with innovative tools that facilitate breakthroughs in immunology and therapeutic development. By choosing the CD70 recombinant antibody, researchers can advance their studies with confidence, unraveling the complexities of immune interactions and paving the way for new therapeutic strategies

Hot Selling Product

ALP64647-Recombinant Human CD70/CD27L Protein, Fc Tag

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64514-Recombinant Human 5T4/TPBG Protein, Avi Tag, His Tag

Expert Choice of cd70 recombinant antibody Where Innovation Meets 2025 Winning in 2025

In the rapidly advancing field of biotechnology, the quest for high-quality reagents and antibodies is paramount. Alpha Lifetech Inc., founded by a team of accomplished scientists, is at the forefront of this innovation. With extensive expertise in membrane Protein production, nanobody discovery, and monoclonal development, our company has successfully launched nearly 10,000 superior reagents, including spot membrane protein reagents, cytokines, and drug target antibodies. Among our premier offerings is the CD70 recombinant antibody, designed using state-of-the-art technology to meet the precise needs of researchers and clinicians worldwide. As we look towards 2025, Alpha Lifetech Inc. is dedicated to not only providing exceptional products but also cultivating partnerships that foster discovery and innovation in the life sciences sector. The Expert Choice of our CD70 recombinant antibody exemplifies our commitment to excellence and reliability. By equipping global researchers with the tools they need to advance their work, we aim to win together in 2025 and beyond. Join us in exploring how our groundbreaking research and high-quality product offerings can help accelerate your scientific pursuits and contribute to transformative solutions in medicine and biotechnology.

Expert Choice of CD70 Recombinant Antibody: Where Innovation Meets 2025 Winning in 2025

Dimension	Details
Antibody Type	Recombinant Monoclonal Antibody
Target	CD70 Protein
Application	ELISA, Western Blot, IHC
Production Method	In vitro Expression System
Purity	>95%
Storage Condition	-20°C, Avoid Freeze/Thaw Cycles
Shelf Life	2 Years
Recommended Dilution	1:100 - 1:500
Cross Reactivity	Minimal to None
Regulatory Status	Research Use Only (RUO)

CD70 Recombinant Antibody Innovation Projection (2021-2025)

This bar chart illustrates the projected Innovation Index for CD70 recombinant antibodies from 2021 through 2025. The data indicates a significant upward trend in innovation, culminating in an index value of 100 in 2025. The increase reflects advancements in biotechnology, enhanced research methodologies, and a growing understanding of CD70-targeted therapies. This period demonstrates the commitment of the scientific community to push the boundaries of antibody engineering and therapeutic applications. As both the prevalence of diseases requiring such therapies and the demand for more effective treatments rise, the innovation index serves as a benchmark for evaluating progress and prioritizing research investments in this vital area of immunology. By 2025, we anticipate not only improvements in antibody design and efficiency but also the exploration of new applications and synergistic effects with existing therapies, ultimately contributing to better patient outcomes.